In a historic development for HIV treatment worldwide, Dr. Reddy’s Laboratories has announced a new partnership with Gilead Sciences to manufacture and commercialize a revolutionary drug called Lenacapavir. This voluntary licensing agreement, unveiled on October 2, 2024, grants Dr. Reddy’s rights to produce and market the drug in India and 120 other countries. The collaboration […]
In a groundbreaking development in the fight against HIV, a 60-year-old German man has been declared free of the virus, marking only the seventh such case in the 40-year history of the AIDS epidemic. This rare and significant medical milestone was achieved through a stem cell transplant, a procedure that combines high risks with painful […]
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their collaborative study, ARC-9, during an oral session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase 1b/2 study assessed the efficacy of etrumadenant combined with zimberelimab, FOLFOX chemotherapy, and bevacizumab (EZFB) in treating […]
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a staggering $4.3 billion, a move that substantially strengthens Gilead’s position in the liver disease treatment landscape. The acquisition brings CymaBay’s leading investigational product, seladelpar, under Gilead’s expanding liver portfolio, marking a significant step forward in the […]
In a significant move within the biopharmaceutical industry, Gilead Sciences, Inc. (Nasdaq: GILD) has confirmed its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a notable $32.50 per share in cash, culminating in a total equity value of $4.3 billion. This strategic acquisition brings CymaBay’s leading investigational product, seladelpar, into Gilead’s portfolio, potentially transforming the […]
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their collaboration agreement, accompanied by a substantial $320 million equity investment by Gilead in Arcus common stock at $21.00 per share. This strategic investment and collaboration amendment are set to accelerate the growth of their joint development programs […]
Strides Pharma Science Limited has announced a significant achievement, with its wholly-owned subsidiary, Strides Pharma Global Pte. Limited in Singapore, receiving approval from the United States Food & Drug Administration (USFDA) for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumarate (300mg) tablets, abbreviated as EET. This approval marks another milestone in Strides’ growing portfolio of products […]
Gilead Sciences, Inc. announced early data showcasing promising clinical activity of Trodelvy in combination with Merck’s KEYTRUDA for first-line treatment of metastatic non-small cell lung cancer (NSCLC). The data was presented at the IASLC 2023 World Conference on Lung Cancer and focuses on patients without actionable genomic alterations. EVOKE-02 Preliminary Analysis: Notable Response Rates Across […]
In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences’ Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering from unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have undergone endocrine-based therapy, and at least two more systemic therapies in the advanced phase. This medication is now […]
New data presented by Gilead Sciences, Inc. has highlighted the efficacy, safety, and patient tolerability of Sunlenca (lenacapavir), the first long-acting injectable HIV treatment administered twice yearly. The data came from the Phase 2/3 CAPELLA trial, including patient-reported outcomes (PRO), demonstrating lenacapavir’s potential in transforming HIV clinical care. The findings were unveiled at the 12th […]